Social Media Ideas for Bmrn

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUSâ„¢, the Fir...

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's r...

BioMarin to acquire Alesta Therapeutics for up to $490 million

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment.

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

<![CDATA[BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment ]]>

Immuron reports FY results

BioRestorative Therapies Announces Reverse Stock Split

MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical…

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

New 3870 pump production ramp compressed margins but bookings doubled shipments.

BioMarin axes $270M rare disease asset after missing phase 3 endpoint

BioMarin Pharmaceutical has ended development of BMN 401 in all indications months after reporting mixed phase 3 data on the rare disease prospect.

BioXcel

BioXcel Anonymous (not verified) Sun, 08/30/2026 - 09:43 field_thread_url https://cafepharma.com/boards/threads/bioxcel.674502/ board na...

BioMarin acquires experimental drug for rare bone disorder in $275M deal

The Alesta buyout helps restock BioMarin's pipeline with an asset it says could “reach our largest addressable patient population,” joining other muscle and skeletal disease treatm...

Repligen: Acquisition To Add Cell Therapy Capabilities

BioXcel files for Chapter 11, will sell assets to Teva

Moonwalk reloads with $70M and new RNAi prospects for obesity

The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.

What This Immunome Sale Means a Day Before a Big FDA Milestone

Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.

Neonatal BDNF Levels Linked to Respiratory Disease in Extremely Preterm Infants

A molecule best known for helping neurons survive and form connections may also provide an early biological signal of respiratory disease in the most vulnerable newborns. In a stud...

Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum

Bimini outlines NOL runway to $5.5M by end of 2028 while integrating TJIM’s $1.7B AUM platform

<![CDATA[Pharmaceutical Executive Daily: BioMarin and n-Lorem Foundation Enter Collaboration]]>

Biofrontera (BFRI) Q2 2026 Earnings Call Transcript

Gross margins expanded 920 basis points as restructured costs offset ITC lamp restrictions.